PeptideScanner

Afamelanotide official document review · version 1

This page preserves this version's findings, scope and source pins. Open the current profile →

Inside the official reviews

Reviewed 2026-09-16 · Preserved version 1

What did FDA find beyond the headline result?

FDA’s 2019 review supported approval for increased pain-free light exposure in adults with erythropoietic protoporphyria. In CUV039, the sponsor’s analysis gave p=0.044; FDA’s analysis including missing-data assumptions gave p=0.055. FDA considered CUV029 supportive, while CUV030’s pain-free exposure analysis was post hoc. FDA PDF pp. 19, 20, 118 ↗

More findings, study links and document coverage

Which limitations affect interpretation?

FDA described diary-design and data-handling problems, different exposure windows and follow-up periods, and uncertainty about the quality-of-life instruments. Twenty-six participants from CUV030 could re-enroll in CUV039, so the trial enrollment totals do not represent entirely distinct people. FDA PDF pp. 21, 117, 118, 119 ↗

What safety work was requested?

The 2019 review requested a cardiac-repolarization study and a long-term registry addressing skin cancer, implant reactions, pregnancy and device issues. These were surveillance questions, not proof that the medicine caused those outcomes. Their current completion status has not been verified in this review. FDA PDF pp. 144, 147, 148 ↗

Read the separate U.S. label account → Label version and indication scope are preserved there; these agency reviews describe their own dated evidence.

Matched study identities

Protocol identifiers were matched to ClinicalTrials.gov records. This does not count extensions as new independent trials.

Document coverage

Selected sections read in 1 of 16 inventoried documents; 15 not yet reviewed. Reading selected sections does not establish complete appraisal of a document.

English PDF entries containing Scenesse in the title in the retained September 15 EMA document-feed snapshot, plus selected FDA approval-package documents. Includes candidate associations, not a complete FDA inventory, national authorizations or worldwide coverage. Live EMA page requests returned HTTP 429 on September 16; fresh page reconciliation is pending. EMA inventory source ↗

Inspect documents, application identities and source pins

Page references use one-based PDF file pages, which can differ from printed page numbers. Candidate feed associations are not verified application identities.

Remaining work

  • Review the remaining EMA assessment, product-information, risk-management and change documents; reconcile historical applications separately.
  • Reconcile later FDA supplements and current postmarketing-study status. Earlier review conclusions are dated evidence, not a current approval-status substitute.
  • Complete full-text and correction appraisal of the related literature. Registry identity matching does not establish that all posted results or historical registry versions have been reviewed.

Open versioned document coverage and study pins →

Public beta · Selective source coverageNot medical advice · No dosing or purchasing guidance